Mutational and clinical characteristics for patients treated or untreated with ICB
| Variables | Patients treated with ICB N=545 | Patients untreated with ICB N=2466 |
| FGF2 status | ||
| Amplification | 32 (6) | 864 (35) |
| No amplification | 513 (94) | 1602 (65) |
| FGF/FGFR status | ||
| FGFAmp/FGFRAmp | 115 (21) | 1487 (60) |
| FGFAmp/FGFRNo Amp | 86 (16) | 459 (19) |
| FGFNo Amp/FGFRAmp | 36 (6.6) | 53 (2) |
| FGFNo Amp/FGFRNo Amp | 308 (57) | 467 (19) |
| Cancer type | ||
| Breast | 15 (2.8) | 1065 (43) |
| Colorectal | 20 (3.7) | 451 (18) |
| Lung | 67 (12) | 498 (20) |
| Melanoma | 364 (67) | 452 (18) |
| Other | 79 (14.5) | – |
| Treatment regimen | ||
| ICB monotherapy | 456 (84) | – |
| ICB in combination | 88 (16) | – |
| NA | 1 | – |
| Number line at ICB | ||
| 1 | 203 (37) | – |
| 2 | 232 (43) | – |
| ≥3 | 110 (20) | – |
Categorical variables were described by number of observations and percentages (%).
Amp, amplification; FGF2, fibroblast growth factor 2; FGFR, FGF receptor; ICB, immune checkpoint blockade; NA, not available; No Amp, no amplification.